Document text
Principal Investigator: STEVEN E REIS
Organization: UNIVERSITY OF PITTSBURGH AT PITTSBURGH
Fiscal Year: 2021
Award: $976,487
Funding agency: National Center for Advancing Translational Sciences
ABSTRACT
The pandemic prompted by the novel SARS-COV-2 virus continues to have a devastating effect on the
physical, social, and economic health of communities throughout the world. To evaluate the sero-prevalence of
immunity against SARS-COV-2 in the United States, this scientific partnership of Clinical and Translational
Science Awardees (CTSAs) at academic medical centers (University of Alabama and University of Pittsburgh)
and the National Institute of Allergy and Infectious Diseases (NIAID) Laboratory of Infectious Disease
identified, enrolled, and obtained blood samples from 11,300 adults who have not been diagnosed with
COVID-19 representing almost every county in the US and all major racial and ethnic groups. We will now
seek consent from these participants to provide follow-up data and blood samples and 6 and 12 months after
enrollment (Aim 1) and determine the immune attributes associated with health outcomes (Aim 2), including
for those in underrepresented populations and across the life course. This collaborative partnership of the
intramural NIAID program and extramurally funded CTSA Hubs will efficiently survey, obtain blood samples
from, and determine changes in the prevalence of SARS-CoV-2 antibodies in a large, heterogeneous cohort of
adults without known clinical COVID-19 disease. Knowledge gained from this seroprevalence study will
advance our understanding of SARS-CoV-2 humoral immunity at the population level and inform population
strategies for vaccination – both for the COVID-19 pandemic and future epidemics involving novel pathogens.
Terms: <19S Gamma Globulin><2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV S protein><2019-nCoV spike glycoprotein><2019-nCoV spike protein><21+ years old><7S Gamma Globulin><Academic Medical Centers><Active Follow-up><Adult><Adult Human><Alabama><Antibodies><Antibody titer measurement><Assay><Back><Bioassay><Biologic Assays><Biological Assay><Biological Markers><Blood Sample><Blood Serum><Blood specimen><COVID crisis><COVID epidemic><COVID pandemic><COVID-19><COVID-19 S protein><COVID-19 antibody><COVID-19 crisis><COVID-19 detection><COVID-19 diagnosis><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 immunity><COVID-19 outbreak><COVID-19 pandemic><COVID-19 public health crisis><COVID-19 spike glycoprotein><COVID-19 spike protein><COVID-19 virus><COVID19><COVID19 detection><COVID19 S protein><COVID19 crisis><COVID19 diagnosis><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 immunity><COVID19 outbreak><COVID19 pandemic><COVID19 public health crisis><COVID19 spike glycoprotein><COVID19 spike protein><COVID19 virus><CV-19><CV19><Clinical><Clinical Sciences><CoV-2><CoV2><Communicable Diseases><Community Health><Consent><County><Data><Development><Diagnostic Reagent Kits><Disease><Disorder><Dorsum><ELISA><EXTMR><Economics><Enrollment><Enzyme-Linked Immunosorbent Assay><Epidemic><Ethnic People><Ethnic Population><Ethnic group><Ethnicity People><Ethnicity Population><Extramural><Extramural Activities><Funding><Future><General Population><General Public><Geography><Health><Herd Immunity><Home><Humoral Immunities><IgG><IgM><Immune><Immune response><Immunes><Immunity><Immunoglobulin G><Immunoglobulin M><Immunological response><Individual><Infection><Infectious Disease Pathway><Infectious Diseases><Infectious Diseases / Laboratory><Infectious Diseases Research><Infectious Disorder><Institutes><Knowledge><Length of Life><Life Cycle><Life Cycle Stages><Longevity><Measures><Monitor><Morbidity><Morbidity - disease rate><NIAID><National Institute of Allergy and Infectious Disease><Natural History><Outcome><Participant><Phase><Population><Prevalence><Race><Racial Group><Racial Stocks><Recontacts><SARS corona virus 2><SARS-CoV-2><SARS-CoV-2 S protein><SARS-CoV-2 antibody><SARS-CoV-2 detection><SARS-CoV-2 diagnosis><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 immunity><SARS-CoV-2 outbreak><SARS-CoV-2 pandemic><SARS-CoV-2 spike glycoprotein><SARS-CoV-2 spike protein><SARS-CoV2><SARS-CoV2 S protein><SARS-CoV2 antibody><SARS-CoV2 epidemic><SARS-CoV2 outbreak><SARS-CoV2 pandemic><SARS-CoV2 spike glycoprotein><SARS-CoV2 spike protein><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Sampling><Seroprevalences><Serum><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 S protein><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 immunity><Severe acute respiratory syndrome coronavirus 2 outbreak><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 spike glycoprotein><Severe acute respiratory syndrome coronavirus 2 spike protein><Severe acute respiratory syndrome related corona virus 2><Special Population><Survey Instrument><Surveys><Testing><Translational Research><Translational Science><Underrepresented Groups><Underrepresented Populations><United States><Universities><University Medical Centers><Viral><Virus><Wuhan coronavirus><active followup><adulthood><antibody against COVID-19><antibody against SARS-CoV-2><antibody against SARS-CoV2><antibody against coronavirus disease 2019><antibody against severe acute respiratory syndrome coronavirus 2><antibody based detection><antibody based test><antibody detection><antibody test><antibody titering><antibody to COVID-19><antibody to SARS-CoV-2><antibody to SARS-CoV2><antibody to coronavirus disease 2019><antibody to severe acute respiratory syndrome coronavirus 2><antibody-based immunity><bio-markers><biologic marker><biomarker><clinical center><cohort><community-based health><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><coronavirus disease 2019><coronavirus disease 2019 S protein><coronavirus disease 2019 antibody><coronavirus disease 2019 crisis><coronavirus disease 2019 detection><coronavirus disease 2019 diagnosis><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 immunity><coronavirus disease 2019 outbreak><coronavirus disease 2019 pandemic><coronavirus disease 2019 public health crisis><coronavirus disease 2019 spike glycoprotein><coronavirus disease 2019 spike protein><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><detect COVID-19><detect COVID19><detect SARS-CoV-2><detect antibodies><detect severe acute respiratory syndrome coronavirus 2><developmental><diagnosed with COVID-19><diagnosed with COVID19><diagnosed with SARS-CoV-2><diagnosed with coronavirus 2019><diagnosed with coronavirus disease 2019><diagnostic kit><emerging pathogen><enroll><ethnicity group><follow up><follow-up><followed up><followup><hCoV19><health economics><host response><immune system response><immunity against COVID-19><immunity against COVID19><immunity against SARS-CoV-2><immunity against Severe acute respiratory syndrome coronavirus 2><immunity against coronavirus disease 2019><immunity to COVID-19><immunity to COVID19><immunity to SARS-CoV-2><immunity to Severe acute respiratory syndrome coronavirus 2><immunity to coronavirus disease 2019><immunoresponse><insight><life course><life span><lifespan><mortality><nCoV2><new pathogen><novel><novel pathogen><novel virus><pandemic><pandemic disease><pathogen><programs><response><screening><severe acute respiratory syndrome coronavirus 2 antibody><severe acute respiratory syndrome coronavirus 2 detection><severe acute respiratory syndrome coronavirus 2 diagnosis><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><social><test kit><translation research><under representation of groups><under represented groups><under represented populations><underrepresentation of groups><vaccination strategy>